Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $280
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Outperform and raises the price target from $252 to $280.